Gujarat Kidney and Super Speciality Ltd AGM Details and FY26 Financials

Revenue grew 14.03% to Rs 40.10 crore in FY 2025-26; Profit After Tax rose 8.70% to Rs 9.90 crore.

Reader Takeaway: Expansion-driven borrowing and investment mandates are on the agenda, balanced by a need for improved regulatory compliance.

What just happened

Gujarat Kidney and Super Speciality Limited has scheduled its 7th Annual General Meeting (AGM) for September 28, 2026. The board is seeking shareholder approval for several significant corporate actions, including raising the company's borrowing and investment powers to Rs 500 crore under Section 186 of the Companies Act. Shareholders will also vote on a substantial salary revision for leadership, with the Managing Director’s pay proposed to rise to Rs 36 lakh annually.

Why this matters

The company is aggressively scaling operations following its December 2025 IPO. Having acquired 100% stakes in Harmony Medicare and Parekhs Hospital during the year, the increased borrowing limit indicates management's intent to sustain this inorganic growth trajectory. The regularization of new independent directors also signals a move toward strengthening corporate governance structure.

Governance and Compliance

The latest secretarial audit for FY 2025-26 highlighted two procedural lapses: a delay in submitting quarterly results for the period ended September 30, 2025, and a failure to provide timely intimation for a board meeting. Investors should track how the management strengthens internal compliance controls to avoid such regulatory observations in future filings.

Context metrics (FY 2025-26 vs FY 2024-25)

• Revenue: Rs 40.10 crore vs Rs 35.17 crore
• Profit Before Tax: Rs 12.55 crore vs Rs 12.10 crore
• Profit After Tax: Rs 9.90 crore vs Rs 9.11 crore